Abstract
Background. Screening for biochemical markers is important for diagnosing colon cancer. In this study, the reliability of serum mesothelin levels as a potential diagnostic and screening instrument was evaluated concerning colon cancer. Methods. Ninety-five patients who had undergone colonoscopic examination and who were diagnosed with colon cancer were included in the study. The serum mesothelin levels were measured with the ELISA kits and were evaluated in terms of significant difference when compared between colon cancer and control group. Results. Patients with colon cancer had significantly higher mesothelin serum levels (P < 0.001) than the control groups. We found significant associations between serum levels and tumor grade, perineural invasion, and vascular invasion (resp., P < 0.001). Conclusion. Evaluating the serum levels of mesothelin has a potential to detect and screen the colon cancer in affected patients. Our data suggest that mesothelin exhibits effects towards colon cancer and serves as a biomarker for this deadly disease.
Highlights
Colon cancer is one of the most common malignancies worldwide and represents a global health problem [1]
The serum mesothelin levels were significantly higher in the patients with colon cancer than in the control group (P < 0.0001) (Table 3)
The serum mesothelin levels were significantly correlated with distant metastasis, lymph node metastasis, and lymph vascular involvement (P = 0.004, P = 0.005, and P = 0.003). This analysis of 95 colon cancer patients indicated that serum mesothelin levels might be of predictive value in colon cancer, especially in the analysis of the clinical stage
Summary
Colon cancer is one of the most common malignancies worldwide and represents a global health problem [1]. The classical noninvasive and invasive methods of screening modalities involve occult blood in stool testing, fecal immunochemical testing, double-contrast barium enema, flexible sigmoidoscopy, and colonoscopy [5]. Some of these screening modalities have been reported to reduce the rate of malignancy or mortality, cancer-related mortality can be reduced by dissolving premalignant adenomas and early localized cancer prior to the development of more advanced stages. Evaluating the serum levels of mesothelin has a potential to detect and screen the colon cancer in affected patients. Our data suggest that mesothelin exhibits effects towards colon cancer and serves as a biomarker for this deadly disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
